Caplin Point Laboratories Ltd.
Snapshot View

913.95 +53.40 ▲6.2%

05 August 2021, 04:00:00 P.M.
Volume: 51,143

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.caplinpoint.net
Financial Indicators
Market Cap 6,913.37 Cr.
Earnings per share (EPS) 32.03 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 28.53 Trailing Twelve Months Ending 2021-03
Industry PE 32.75 Trailing Twelve Months Ending 2021-03
Book Value / Share 156.77 Trailing Twelve Months Ending 2021-03
Price to Book Value 5.83 Calculated using Price: 913.95
Dividend Yield 0.16 Period Ending 2020-03
No. of Shares Subscribed 7.56 Cr. 75,642,750 Shares
FaceValue 2
Company Profile

Caplin Point Laboratories was established in 1990 to manufacture a range of ointments, creams and other external applications. The Company was listed in 1994; the IPO proceeds were deployed in a manufacturing facility in Pondicherry. The promoters exposed their lives to physical risk when they ventured into war-affected countries more than two decades ago. The Company ventured into the emerging markets of West Africa, Latin America and The Caribbean to market finished formulations. The Company’s asset-light marketing business model has helped generate the resources to build world-class infrastructure.

The success of Caplin Point is primarily attributed to its unique business model. Starting of as an SME, Caplin Point decided at an early stage that the conventional style of exports would mean diminishing margins and reduced opportunities for expansion, and had taken the unique step of creating last mile logistical solutions for its exclusive distributors across Latin America and various parts of Africa. This way, Caplin Point is able to generate adequate revenue and cash flow to remain debt-free with benchmark receivables, and also continue to invest in state of the art manufacturing facilities from internal accruals. One of the main reasons for the success can be attributed to the wide range of products offered across diverse geographies.

Business area of the company

Caplin Point is the mid-sized company in India’s pharmaceutical sector to be engaged in the manufacture of APIs, finished formulations, research & development, clinical research, frontend generic presence in Latin America, brand marketing in Francophone Africa and an USFDA approved injectable facility.

Products

  • Liquid Injections
  • Lyophilised Injections
  • Opthalmic
  • Tablets
  • Liquid Orals
  • Capsule
  • Softgel Capsules
  • Suppositories & Ovules
  • Powder for Injection
  • Dry syrup
  • Topicals
  • Liquid Injections
  • Inhalers
  • Ophthalmic
  • IV Infusion
  • Lyophilised Products
  • Branded Products
  • Dermo Cosmetics

Awards and recognitions

  • 2014: Forbes Asia Best under a Billion Award - 2014.
  • 2015: Forbes Asia Best under a Billion Award - 2015.
  • 2016: Forbes Asia Best under a Billion Award - 2016.
  • 2017: Nanayam Vikatan’s Gold Phoenix Award to Mr. C C Paarthipan.
  • 2017: Financial express CFO Awards 2017 (Second Rank).
  • 2017: IPF’s industrial Excellance Award.
  • 2018: The Economic Times - Family Business of the year Award.
  • 2018: Pharmexcil Outstanding Exports Award 2018.
  • 2018: The Economic Times Award for Excellence in Business Performance.
  • 2019: Empowering India Awards 2019 in Pharmaceutical, Healthcare and Bio-Technology Segment.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+6.21%
1 Week
+1.08%
1 Month
+33.19%
3 Month
+74.48%
6 Month
+95.56%
1 Year
+59.41%
2 Year
+121.62%
5 Year
+281.54%
9 years 2012-06 2013-06 2014-06 2015-06 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 29.10 40.49 53.24 55.78 43.13 54.97 49.43 37.14 29.58
Return on Capital Employed (%) 34.62 56.69 68.99 71.11 55.41 69.03 64.08 45.59 33.46
Return on Assets (%) 9.00 11.59 16.48 20.12 18.46 30.54 33.68 28.41 23.02

Balance Sheet View Details

Particulars 9 years 2012-06 Rs. Cr. 2013-06 Rs. Cr. 2014-06 Rs. Cr. 2015-06 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 34 43 62 93 128 225 364 633 948
Non Curr. Liab. 4 9 10 10 14 20 28 23 25
Curr. Liab. 69 83 108 125 125 113 109 86 144
Minority Int. 0 0 0 0 0 0 0 0 9
Equity & Liab. 107 135 180 229 267 358 500 743 1,126
Non Curr. Assets 53 96 131 147 149 179 196 249 303
Curr. Assets 54 39 49 82 119 179 304 494 823
Misc. Exp. not W/O
Total Assets 107 135 180 229 267 358 500 743 1,126

Profit Loss View Details

Particulars 9 years 2012-06 Rs. Cr. 2013-06 Rs. Cr. 2014-06 Rs. Cr. 2015-06 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 107 127 173 252 239 402 540 649 863
Other Income 3 2 4 3 4 10 13 19 41
Total Income 110 129 177 255 242 412 553 668 905
Total Expenditure -96 -105 -137 -192 -175 -277 -345 -417 -602
PBIDT 14 24 40 63 68 135 208 251 302
Interest -1 -1 -1 -1 0 -1 -1 -1 -1
Depreciation -1 -2 -4 -8 -7 -13 -19 -23 -32
Taxation -3 -8 -10 -12 -14 -25 -44 -50 -54
Exceptional Items
PAT 8 14 26 41 46 96 145 177 215

Cash Flow View Details

Particulars 9 years 2012-06 Rs. Cr. 2013-06 Rs. Cr. 2014-06 Rs. Cr. 2015-06 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 28 32 60 50 42 68 66 83 45
Cash Fr. Inv. -16 -45 -44 -23 -6 -36 -69 -100 -55
Cash Fr. Finan. -1 -1 -6 -9 -14 -7 -12 90 80
Net Change 10 -15 10 19 23 25 -14 73 70
Cash & Cash Eqvt 32 17 27 45 68 91 77 151 221

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 69.03 69.03 69.03 69.03 69.03 69.03 69.03 69.03 69.03
Public 30.97 30.97 30.97 30.97 30.97 30.97 30.97 30.97 30.97
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Thu, 05 Aug 2021
Announcement under Regulation 30 (LODR)-Dividend Updates
Recommended a Final Dividend of Rs. 1.50/- (75 %) per equity share of Rs.2 each for the financial year ended 31st March 2021 subject to the approval of the shareholders at the ensuing Annual General Meeting.
Thu, 05 Aug 2021
Board Meeting Outcome for Outcome Of Board Meeting
Outcome of Board Meeting
Thu, 05 Aug 2021
Approved The Un-Audited Standalone And Consolidated Financial Results And The Limited Review Report Of The Company As Per Indian Accounting Standards For The Quarter Ending 30Th June 2021.
Approved the Un-audited standalone and consolidated financial results and the Limited Review Report of the Company as per Indian Accounting Standards for the quarter ending 30th June 2021.

Technical Scans View Details

Thu, 05 Aug 2021
Higher Trade Quantity Higher Trade Quantity
Close Crossing Last Month Close From Below Close Crossing Last Month Close From Below
Closing Above Previous High Closing Above Previous High
Making Lower Lows for 3 days Making Lower Lows for 3 days
Close Within 52 Week High Zone Close Within 52 Week High Zone

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 188,551.74 785.85 +0.0%
Divi's Laboratories Ltd. 130,702.13 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. 79,575.04 4,783.30 +0.2%
Cipla Ltd. 76,243.85 945.20 +0.6%
Cadila Healthcare Ltd. 59,868.47 584.80 -0.5%
Piramal Enterprises Ltd. 59,065.41 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. 58,599.44 4,075.50 +0.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 31.41 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 65.87 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.80 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 31.70 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 28.06 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 44.33 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 389.73 4,075.50 +0.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 3.94 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 14.06 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.45 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 4.17 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 4.61 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 1.73 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.75 4,075.50 +0.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 0.10 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,075.50 +0.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 14.13 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,075.50 +0.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 32.07 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 17.85 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 10.03 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,075.50 +0.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,075.50 +0.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,075.50 +0.2%